News - Report on Innovative Financing into Hepatitis B and C Prevention and Treatment in Low and Middle Income Countries.

VHPB launches report on Innovative Financing into Hep B and C Prevention and Treatment.

Download the:

Read the blog:

Tags: 

News - Presentations Ljublana Meeting 'Highlight underserved for screening, prevention and treatment of viral hepatitis B and C in Europe'

The presentations of the VHPB meeting in Ljublana on 10 and 11 March 2016 on: 'Highlight underserved for screening, prevention and treatment of viral hepatitis B and C in Europe' are online.

Tags: 

News - ELPA launches Hepatitis B and C - An Action Plan for Saving Lives in Europe

Hepatitis B and C - An Action Plan for Saving Lives in Europe

Over the past four decades, we have seen a significant increase in people across Europe being affected by hepatitis B and C; both serious, asymptomatic, infectious diseases that kill around 120,000 people in Europe every year.1 In response to this, a large body of work has been produced over the past three years, giving information and recommendations on how to address the burden of the disease.

Tags: 

News - Presentations Riga Meeting 'Prevention and control of viral hepatitis in the Baltic States: lessons learnt and the way forward'

Prevention and control of viral hepatitis in the Baltic States: lessons learnt and the way forward.

The presentations of the VHPB meeting in Riga on 19 and 20 November 2015 are now online.

 

Tags: 

News - Hepatitis C Elimination Manifesto

Hepatitis C Elimination Manifesto

The ‘Hepatitis C Elimination Manifesto’ was presented at the first EU HCV Policy Summit, organised by the Hepatitis B and C Public Policy Association, and supported by the main European patient and clinician groups. In the ‘Hepatitis C Elimination Manifesto’, 'Europe’s leading experts, medical specialists and patient advocacy groups on hepatitis announced their intention to work towards the elimination of Hepatitis C Virus (HCV) in Europe by 2030.

Tags: 

News - 2015 EASL Recommendations on Treatment of Hepatitis C

EASL Recommendations on Treatment of Hepatitis C 2015

In 2015, EASL released updated recommendations on treatment of hepatitis C. These recommendations are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic hepatitis C infections.

Tags: 

News - 2015 World Hepatitis Summit

World Hepatitis Summit

From 2-4 September, the World Hepatitis Summit was held in order to upscale the world’s response to hepatitis and to address the need for a global forum to examine public health approaches to the disease. The Summit is a joint World Health Organization (WHO) and World Hepatitis Alliance (WHA).

The Summit resulted in the Glasgow Declaration on Hepatitis.

Tags: 

News - 2015 World hepatitis Day July 28

July 28th World Hepatitis Day

The VHPB endorses the World hepatitis day on 28 July. Therefor we would like to invite you to visit the website of the related organisation who are active today in raising awareness about viral hepatitis, and  urge policy-makers, health workers and the public to act now to prevent infection and death from hepatitis.

Tags: 

News - 2014 Partners sign call to action on hepatitis

Partners sign call to action on hepatitis

Participants of the first global partners' meeting on hepatitis convened by WHO in March 2014 agree on a historic "Call to action to scale up global hepaitis response". The "call to action" presses the global community for immediate and concerted action to increase access to prevention, diagnosis and treatment of viral hepatitis. 

Tags: 

News - 2014 WHO issues its first hepatitis C treatment guidelines

WHO issues its first hepatitis C treatment guidelines

These are the first guidelines dealing with hepatitis C treatment produced by the World Health Organization (WHO) and complement existing guidance on the prevention and transmission of bloodborne viruses, including HCV. They are intended for policy-malers, government officials and other working in low- and middleincome countries who are developing programmes for the screening, care and treatment of persons with HCV infection.

Tags: 

Pages